Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; 14 of the 28 sources its claims cite were checked for support.
Abstract
Histone H3 lysine(27)-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas. We established a Drosophila animal model for the pathogenic histone H3K27M mutation and show that its overexpression resembles polycomb repressive complex 2 (PRC2) loss-of-function phenotypes, causing derepression of PRC2 target genes and developmental perturbations. Similarly, an H3K9M mutant depletes H3K9 methylation levels and suppresses position-effect variegation in various Drosophila tissues. The histone H3K9 demethylase KDM3B/JHDM2 associates with H3K9M-containing nucleosomes, and its misregulation in Drosophila results in changes of H3K9 methylation levels and heterochromatic silencing defects. We have established histone lysine-to-methionine mutants as robust in vivo tools for inhibiting methylation pathways that also function as biochemical reagents for capturing site-specific histone-modifying enzymes, thus providing molecular insight into chromatin signaling pathways.
Overview
CoChat Summary
TL;DR
This paper establishes Drosophila models in which histone H3 lysine-to-methionine mutants (H3.3K27M and H3.3K9M) are overexpressed to inhibit histone methylation pathways in vivo. It shows H3.3K27M phenocopies PRC2 loss and H3.3K9M depletes H3K9 methylation, suppresses position-effect variegation, and captures KDM3B/JHDM2 and SIRT6 as H3K9M-associated factors.
Key findings
- Overexpressing H3.3K27M in Drosophila wing imaginal discs strongly reduces H3K27 methylation and derepresses the PRC2 target gene Ultrabithorax (Ubx), phenocopying E(z) knockdown; RNA-seq shows upregulated Polycomb targets including Ubx, wingless (wg), and Psc, and downregulated Hox/signaling genes including engrailed (en), invected (in), and cubitus interruptus (ci). Tissue-specific Distalless-GAL4 expression causes gross morphological defects and death around eclosion.
- H3.3K9M overexpression globally depletes H3K9 methylation without affecting H3K27 methylation. MudPIT of mononucleosomes from HEK293 cells shows dramatically reduced binding of HP1a (CBX5), HP1β (CBX1), HP1γ (CBX3), CHAF1A/p150, and CHAF1B/p60, and dramatically increased association of KDM3B and SIRT6.
- H3.3K9M suppresses position-effect variegation (PEV) in salivary glands and eye-antenna imaginal discs and derepresses gypsy-lacZ in ovaries. JHDM2 depletion increases H3K9 methylation, whereas JHDM2 overexpression depletes H3K9 methylation and suppresses PEV; Sirt6 RNAi derepresses gypsy-lacZ, but Sirt6 shows no major PEV effects in eye-antenna imaginal discs and salivary glands.
Methods
- Generated UAS-H3.3WT-FLAG-HA, UAS-H3.3K9M-FLAG-HA, and UAS-H3.3K27M-FLAG-HA Drosophila lines and used tissue-specific GAL4 drivers for overexpression in wing imaginal discs, salivary glands, eye-antenna imaginal discs, and ovaries; assays included immunofluorescence, X-Gal PEV staining, and genome-wide RNA-seq.
- HEK293 TRex FLP-in cells with doxycycline-inducible histone constructs were induced with 1 µg/ml doxycycline for 4 days; mononucleosomes were prepared by micrococcal nuclease digestion and anti-FLAG immunoprecipitation from ~7.5×10^8 cells per IP, then analyzed by MudPIT mass spectrometry and dNSAF.
- Main analyses were immunostaining/microscopy, RNA-seq of wing discs, PEV silencing assays, and proteomic interaction profiling of mononucleosomes.
Limitations
- Stated limitations: Not stated in the paper.
- Evident: The H3K27M model relies on GAL4-driven overexpression of tagged H3.3 in Drosophila rather than endogenous heterozygous H3.3K27M as in pediatric gliomas; the paper states the model “may help elucidate” glioma pathogenesis.
- Evident: Biochemical capture of H3K9M interactors was performed in HEK293 cells, while functional H3K9M/JHDM2/Sirt6 assays were in Drosophila; the paper notes that H3K9M mutations in cancers are plausible but as-yet uncharacterized.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 5 Not checked · 27 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Additional histone H3 lysine-to-methionine mutants possess dominant gain-of-function activities [6]”
§ Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling > Abstract
What the sources say
- Supportedcites [6] Lewis PW Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma Science 2013 340 6134 857 61 23539183 PMC3951439 source
The paper reports that H3K9M and H3K36M transgenes reduce methylation at their respective residues. Its concluding passage (labelled Abstract in our copy) describes K-to-M mutations as a gain-of-function mechanism and says mutant histones comprising only a few percent of total histones can prevent global methylation, supporting the claim of dominant activity. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“act in a dominant manner to deplete H3K27 methylation by inhibiting PRC2 methyltransferase activity [5, 6]”
§ Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling > Abstract
What the sources say
- Partly supportedcites [5] Chan KM The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression Genes Dev 2013 27 9 985 90 23603901 PMC3656328 sourceExperimental — accuracy not yet measured
The Results and Discussion report that low-level H3.3K27M expression dramatically reduced endogenous H3K27me2 and H3K27me3, supporting a dominant effect. The paper identifies PRC2 as the H3K27 methyltransferase, but the passages in our copy do not establish that inhibition of its methyltransferase activity is the mechanism. (LLM, conf=0.86)
- Supportedcites [6] Lewis PW Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma Science 2013 340 6134 857 61 23539183 PMC3951439 source
The Abstract (passage 7) reports that H3K27M reduces overall H3K27me3 and inhibits PRC2 enzymatic activity. Passage 6 shows reduced methylation on endogenous wild-type H3 alongside H3K27M, supporting the description of a dominant effect. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Histone H3 lysine27-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.”
- Also stated in: § Abstract · plain
“Single allele mutations of histone H3.3 lysine27-to-methionine (H3.3K27M) occur in a subtype of aggressive pediatric brain cancers [3, 4]”
§ Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling > Abstract
What the sources say
- Not checked — no full text of the sourcecites [3] Schwartzentruber J Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma Nature 2012 482 7384 226 31 22286061 source
- Partly supportedcites [4] Wu G Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas Nat Genet 2012 44 3 251 3 22286216 PMC3288377 sourceExperimental — accuracy not yet measured
The Abstract reports monoallelic p.K27M substitutions in histone H3 genes, including H3F3A (H3.3), in pediatric high-grade gliomas. It says these substitutions suggest a gain-of-function effect, but that further studies are required to determine their functional impact; the citing sentence states gain of function as established. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Histone H3K9me3 serves as a binding substrate for heterochromatin protein 1 (HP1) [9–12]”
§ Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling > Abstract
What the sources say
- Could not verifycites [9] James TC Elgin SC Identification of a nonhistone chromosomal protein associated with heterochromatin in Drosophila melanogaster and its gene Molecular and cellular biology 1986 6 11 3862 72 3099166 PMC367149 sourceExperimental — accuracy not yet measured
Our copy of James & Elgin (1986) consists of the bibliographic header, the abstract (identification of a 19-kDa Drosophila nuclear protein localized by immunofluorescence to alpha, beta and intercalary heterochromatin, its cDNA and gene at 29A) and the reference list; nothing in it addresses histone H3 lysine 9 trimethylation or a methylation-dependent binding mechanism for HP1. Searches for 'histone H3 lysine 9 methylation binding site HP1' and 'methylated DNA histone modification recognition chromodomain' returned only the abstract and reference-list passages (semantic matches, scores ~0.70-0.75), i.e. no passage states or contradicts the claim. The paper identifies the heterochromatin-associated protein itself but says nothing about H3K9me3 as its ligand, so this source cannot support the attributed mechanistic statement. (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [10] Bannister AJ Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain Nature 2001 410 6824 120 4 11242054 source
- Not checked — no full text of the sourcecites [11] Nakayama J Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly Science 2001 292 5514 110 3 11283354 source
- Partly supportedcites [12] Lachner M Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins Nature 2001 410 6824 116 20 11242053 sourceExperimental — accuracy not yet measured
Our copy of James & Elgin (1986) identifies the protein the citing sentence names: the Abstract (p. 3862) describes monoclonal antibodies against a 19-kilodalton nuclear protein of D. melanogaster whose antigen is localized by immunofluorescence to the alpha, beta and intercalary heterochromatic regions, plus the cloning and mapping of its gene to 29A on 2L — i.e., the original HP1 identification. However, no passage in our copy (Abstract, or the reference lists pp. 3870–3872 returned by searches for 'HP1 / methylated histone H3 lysine 9' and 'protein binds methylated DNA heterochromatin association mechanism') addresses histone H3 K9 methylation as a binding substrate; the binding described is of the protein fraction 'tightly binding to DNA'. The H3K9me3-recognition half of the claim is therefore not supported by this source, which can stand only as the identification of HP1 itself. (LLM, conf=0.68)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“thus phenocopying knockdown of the catalytic PRC2 subunit E(z) (fig. S2)”
- Also stated in: § Abstract · plain
“show that its overexpression resembles Polycomb repressive complex 2 (PRC2) loss-of-function phenotypes”
§ Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
27 more claims
Create a free account to see all 44 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“however, our previous biochemical purifications of mono-nucleosomes containing H3K27M did not show any preferential enrichment for PRC2 subunits5.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Expression of the histone mutant is accompanied by a reduction in the levels of Polycomb Repressive Complex 2 (PRC2) mediated H3K27 trimethylation (H3K27me3) and this is purported to be a driving event of DIPG oncogenesis4,5.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“As shown by our group and others, H3K27M expression is associated with increased levels of H3K27ac4,5 (Fig. 1D).”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [5]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These results support the increased association of acetyl-binding bromodomain proteins to H3K27M containing nucleosomes5, and prompted us to investigate the role of these proteins in DIPG cells.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [5]
Experimental — accuracy not yet measured
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347
Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain
Bannister, A. J., Zegerman, P., Partridge, J. F., Miska, E. A., Thomas, J. O., Allshire, R. C., & Kouzarides, T. (2001) · Nature · doi:10.1038/35065138 · Cited by 2,903
Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins
Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., & Jenuwein, T. (2001) · Nature · doi:10.1038/35065132 · Cited by 2,868
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631 · cited 2×
“3K27M) occur in a subtype of aggressive pediatric brain cancers [3, 4], and act in a dominant manner to deplete H3K27 methylation by inhibiting PRC2 methyltransferase activity [5, 6].”
BackgroundLoss of the Suv39h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome Stability
Peters, A. H. F. M., O'Carroll, D., Scherthan, H., Mechtler, K., Sauer, S., Schöfer, C., Weipoltshammer, K., Pagani, M., Lachner, M., Kohlmaier, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00542-6 · Cited by 1,766
Role of Histone H3 Lysine 9 Methylation in Epigenetic Control of Heterochromatin Assembly
Nakayama, J.-I., Rice, J. C., Strahl, B. D., Allis, C. D., & Grewal, S. I. S. (2001) · Science · doi:10.1126/science.1060118 · Cited by 1,739
St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345 · cited 4×
“3K9M constructs with a Cterminal FLAG-HA tag [6] for tissue-specific overexpression in Drosophila.”
BackgroundMethodInfluential
Cited by
Epigenetic modifications of histones in cancer
Zhao, Z., & Shilatifard, A. (2019) · Genome Biology · doi:10.1186/s13059-019-1870-5 · Cited by 552
Self-citationThe roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
Epigenetic balance of gene expression by Polycomb and COMPASS families
Piunti, A., & Shilatifard, A. (2016) · Science · doi:10.1126/science.aad9780 · Cited by 524
Self-citationTherapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
Piunti, A., Hashizume, R., Morgan, M. A., Bartom, E. T., Horbinski, C. M., Marshall, S. A., Rendleman, E. J., Ma, Q., Takahashi, Y.-H., Woodfin, A. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4296 · Cited by 445
Self-citationSolomon, D. A., Wood, M. D., Tihan, T., Bollen, A. W., Gupta, N., Phillips, J. J. J., & Perry, A. (2016) · Brain Pathology · doi:10.1111/bpa.12336 · Cited by 433
Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma
Nagaraja, S., Vitanza, N. A., Woo, P. J., Taylor, K. R., Liu, F., Zhang, L., Li, M., Meng, W., Ponnuswami, A., Sun, W., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.011 · Cited by 396
Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape
Lu, C., Jain, S. U., Hoelper, D., Bechet, D., Molden, R. C., Ran, L., Murphy, D., Venneti, S., Hameed, M., Pawel, B. R., et al. (2016) · Science · doi:10.1126/science.aac7272 · Cited by 392
Morgan, M. A. J., & Shilatifard, A. (2020) · Nature Genetics · doi:10.1038/s41588-020-00736-4 · Cited by 355
Self-citationNativio, R., Lan, Y., Donahue, G., Sidoli, S., Berson, A., Srinivasan, A. R., Shcherbakova, O., Amlie-Wolf, A., Nie, J., Cui, X., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0696-0 · Cited by 380
Regulation of gene transcription by Polycomb proteins
Aranda, S., Mas, G., & Di Croce, L. (2015) · Science Advances · doi:10.1126/sciadv.1500737 · Cited by 336
Larson, J. D., Kasper, L. H., Paugh, B. S., Jin, H., Wu, G., Kwon, C.-H., Fan, Y., Shaw, T. I., Silveira, A. B., Qu, C., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.11.015 · Cited by 300
Characteristics of H3 K27M-mutant gliomas in adults
Meyronet, D., Esteban-Mader, M., Bonnet, C., Joly, M.-O., Uro-Coste, E., Amiel-Benouaich, A., Forest, F., Rousselot-Denis, C., Burel-Vandenbos, F., Bourg, V., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now274 · Cited by 279
Yu, J.-R., Lee, C.-H., Oksuz, O., Stafford, J. M., & Reinberg, D. (2019) · Genes & Development · doi:10.1101/gad.325050.119 · Cited by 257
Histones: At the Crossroads of Peptide and Protein Chemistry
Müller, M. M., & Muir, T. W. (2015) · Chemical Reviews · doi:10.1021/cr5003529 · Cited by 247
Catarino, R. R., & Stark, A. (2018) · Genes & Development · doi:10.1101/gad.310367.117 · Cited by 210
Germ line–inherited H3K27me3 restricts enhancer function during maternal-to-zygotic transition
Zenk, F., Loeser, E., Schiavo, R., Kilpert, F., Bogdanović, O., & Iovino, N. (2017) · Science · doi:10.1126/science.aam5339 · Cited by 220
Chromatin signatures of cancer
Morgan, M. A., & Shilatifard, A. (2015) · Genes & Development · doi:10.1101/gad.255182.114 · Cited by 219
Self-citationChromatin regulatory mechanisms and therapeutic opportunities in cancer
Valencia, A. M., & Kadoch, C. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0258-1 · Cited by 208
Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma
Stafford, J. M., Lee, C.-H., Voigt, P., Descostes, N., Saldaña-Meyer, R., Yu, J.-R., Leroy, G., Oksuz, O., Chapman, J. R., Suarez, F., et al. (2018) · Science Advances · doi:10.1126/sciadv.aau5935 · Cited by 191
Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy
Wang, L., Zhao, Z., Ozark, P. A., Fantini, D., Marshall, S. A., Rendleman, E. J., Cozzolino, K. A., Louis, N., He, X., Morgan, M. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0034-6 · Cited by 185
Self-citationEGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling
Liu, F., Hon, G. C., Villa, G. R., Turner, K. M., Ikegami, S., Yang, H., Ye, Z., Li, B., Kuan, S., Lee, A. Y., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.09.002 · Cited by 193
Interrogating the Function of Metazoan Histones using Engineered Gene Clusters
McKay, D. J., Klusza, S., Penke, T. J. R., Meers, M. P., Curry, K. P., McDaniel, S. L., Malek, P. Y., Cooper, S. W., Tatomer, D. C., Lieb, J. D., et al. (2015) · Developmental Cell · doi:10.1016/j.devcel.2014.12.025 · Cited by 170
HP1 drives de novo 3D genome reorganization in early Drosophila embryos
Zenk, F. L., Zhan, Y., Kos, P. I., Löser, E., Atinbayeva, N., Schächtle, M., Tiana, G., Giorgetti, L., & Iovino, N. (2021) · Nature · doi:10.1038/s41586-021-03460-z · Cited by 144
H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2
Jain, S. U., Rashoff, A. Q., Krabbenhoft, S. D., Hoelper, D., Do, T. J., Gibson, T. J., Lundgren, S. M., Bondra, E. R., Deshmukh, S., Harutyunyan, A. S., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.09.028 · Cited by 156
Set1/COMPASS and Mediator are repurposed to promote epigenetic transcriptional memory
D'Urso, A., Takahashi, Y.-H., Xiong, B., Marone, J., Coukos, R., Randise-Hinchliff, C., Wang, J.-P., Shilatifard, A., & Brickner, J. H. (2016) · eLife · doi:10.7554/elife.16691 · Cited by 133
Self-citationMechanisms of Polycomb group protein function in cancer
Parreno, V., Martinez, A., & Cavalli, G. (2022) · Cell Research · doi:10.1038/s41422-021-00606-6 · Cited by 168
Nuclear deformation guides chromatin reorganization in cardiac development and disease
Seelbinder, B., Ghosh, S., Schneider, S. E., Scott, A. K., Berman, A. G., Goergen, C. J., Margulies, K. B., Bedi, K. C., Casas, E., Swearingen, A. R., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00823-9 · Cited by 119
Xie, J., Wooten, M., Tran, V., Chen, B., Pozmanter, C., Simbolon, C., Betzig, E., & Chen, X. (2015) · Cell · doi:10.1016/j.cell.2015.10.002 · Cited by 136
Histone H3 Mutations: An Updated View of Their Role in Chromatin Deregulation and Cancer
Lowe, B. R., Maxham, L., Hamey, J. J., Wilkins, M. R., & Partridge, J. F. (2019) · Cancers · doi:10.3390/cancers11050660 · Cited by 143
Piunti, A., Smith, E. R., Morgan, M. A. J., Ugarenko, M., Khaltyan, N., Helmin, K. A., Ryan, C. A., Murray, D. C., Rickels, R. A., Yilmaz, B. D., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax2887 · Cited by 109
Self-citationMutations in chromatin machinery and pediatric high-grade glioma
Lulla, R. R., Saratsis, A. M., & Hashizume, R. (2016) · Science Advances · doi:10.1126/sciadv.1501354 · Cited by 104
Oncohistones: drivers of pediatric cancers
Mohammad, F., & Helin, K. (2017) · Genes & Development · doi:10.1101/gad.309013.117 · Cited by 101
H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers
Dong, F., Gan, H., Cheng, L., Lee, J., Zhou, H., Sarkaria, J. N., Daniels, D. J., & Zhang, Z. (2018) · eLife · doi:10.7554/elife.36696 · Cited by 113
The Histone Variant H3.3 in Transcriptional Regulation and Human Disease
Shi, L., Wen, H., & Shi, X. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.019 · Cited by 119
Arimura, Y., Ikura, M., Fujita, R., Noda, M., Kobayashi, W., Horikoshi, N., Sun, J., Shi, L., Kusakabe, M., Harata, M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky661 · Cited by 96
Histone H3 mutations—a special role for H3.3 in tumorigenesis?
Kallappagoudar, S., Yadav, R. K., Lowe, B. R., & Partridge, J. F. (2015) · Chromosoma · doi:10.1007/s00412-015-0510-4 · Cited by 116
Mechismo: predicting the mechanistic impact of mutations and modifications on molecular interactions
Betts, M. J., Lu, Q., Jiang, Y., Drusko, A., Wichmann, O., Utz, M., Valtierra-Gutiérrez, I. A., Schlesner, M., Jaeger, N., Jones, D. T., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1094 · Cited by 90
Yuan, S., Natesan, R., Rivera, F. J. S., Li, J., Bhanu, N. V., Yamazoe, T., Lin, J., Merrell, A. J., Sela, Y., Thomas, S. K., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1299 · Cited by 98
Cutter, A. R., Taneja, N., Dhakshnamoorthy, J., Wheeler, D. L., Holla, S., & Grewal, S. I. S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100699118 · Cited by 86
Molecular basis for the role of oncogenic histone mutations in modulating H3K36 methylation
Zhang, Y., Shan, C., Wang, J., Bao, K., Tong, L., & Jia, S. (2017) · Scientific Reports · doi:10.1038/srep43906 · Cited by 91
Vitanza, N. A., Biery, M. C., Myers, C. H., Ferguson, E., Zheng, Y., Girard, E. J., Przystal, J. M., Park, G., Noll, A., Pakiam, F. J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa249 · Cited by 79
Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones
Sarthy, J. F., Meers, M. P., Janssens, D. H., Henikoff, J. G., Feldman, H. M., Paddison, P. J., Lockwood, C. M., Vitanza, N. A., Olson, J. M., Ahmad, K., et al. (2020) · eLife · doi:10.7554/elife.61090 · Cited by 76
Direct interrogation of the role of H3K9 in metazoan heterochromatin function
Penke, T. J. R., McKay, D. J., Strahl, B. D., Matera, A. G., & Duronio, R. J. (2016) · Genes & Development · doi:10.1101/gad.286278.116 · Cited by 74
A cryptic Tudor domain links BRWD2/PHIP to COMPASS-mediated histone H3K4 methylation
Morgan, M. A. J., Rickels, R. A., Collings, C. K., He, X., Cao, K., Herz, H.-M., Cozzolino, K. A., Abshiru, N. A., Marshall, S. A., Rendleman, E. J., et al. (2017) · Genes & Development · doi:10.1101/gad.305201.117 · Cited by 68
Self-citationOncogenic Mechanisms of Histone H3 Mutations
Weinberg, D. N., Allis, C. D., & Lü, C. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026443 · Cited by 78
Zheng, Y., Fornelli, L., Compton, P. D., Sharma, S., Canterbury, J., Mullen, C., Zabrouskov, V., Fellers, R. T., Thomas, P. M., Licht, J. D., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.053819 · Cited by 73
Decoding the protein composition of whole nucleosomes with Nuc-MS
Schachner, L. F., Jooß, K., Morgan, M. A., Piunti, A., Meiners, M. J., Kafader, J. O., Lee, A. S., Iwanaszko, M., Cheek, M. A., Burg, J. M., et al. (2021) · Nature Methods · doi:10.1038/s41592-020-01052-9 · Cited by 61
Self-citationMolecular mechanisms and therapeutic targets in pediatric brain tumors
Liu, K.-W., Pajtler, K. W., Worst, B. C., Pfister, S. M., & Wechsler‐Reya, R. J. (2017) · Science Signaling · doi:10.1126/scisignal.aaf7593 · Cited by 71
Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma
Long, W., Yang, Y., Chen, S., Cao, Q., Zhao, W., & Liu, Q. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00495 · Cited by 79
Morgan, M. A., & Shilatifard, A. (2023) · Science Advances · doi:10.1126/sciadv.adg6593 · Cited by 72
Self-citationSignal Transduction in Diffuse Intrinsic Pontine Glioma
Duchatel, R. J., Jackson, E. R., Alvaro, F., Nixon, B., Hondermarck, H., & Dun, M. D. (2019) · PROTEOMICS · doi:10.1002/pmic.201800479 · Cited by 70
Fang, Y., Chen, L., Lin, K., Feng, Y., Zhang, P., Pan, X., Sanders, J. L., Wu, Y., Wang, X., Su, Z., et al. (2019) · Genome Research · doi:10.1101/gr.246009.118 · Cited by 64
Histone H3 Mutations in Cancer
Wan, Y. C. E., Liu, J., & Chan, K. M. (2018) · Current Pharmacology Reports · doi:10.1007/s40495-018-0141-6 · Cited by 63
Brumbaugh, J., Kim, I. S., Ji, F., Huebner, A. J., Stefano, B. D., Schwarz, B. A., Charlton, J., Coffey, A., Choi, J., Walsh, R. M., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0403-5 · Cited by 64
Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma
Zhang, Y., Dong, W., Zhu, J., Wang, L., Wu, X., & Shan, H. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0184-0 · Cited by 67
Gehre, M., Bunina, D., Sidoli, S., Lübke, M. J., Diaz, N. S., Trovato, M., Garcia, B. A., Zaugg, J. B., & Noh, K. (2020) · Nature Genetics · doi:10.1038/s41588-020-0586-5 · Cited by 59
Polycomb Repressive Complex 2 Methylates Elongin A to Regulate Transcription
Ardehali, M. B., Anselmo, A. N., Cochrane, J. C., Kundu, S., Sadreyev, R. I., & Kingston, R. E. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.10.025 · Cited by 65
Chaouch, A., Berlandi, J., Chen, C. C. L., Frey, F., Badini, S., Harutyunyan, A. S., Chen, X., Krug, B., Hébert, S., Jeibmann, A., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.10.008 · Cited by 54
Jung, J. S., Choi, Y. S., Ahn, S. S., Yi, S., Kim, S. H., & Lee, S. (2019) · Neuroradiology · doi:10.1007/s00234-019-02154-8 · Cited by 64
Pleiotropic Functions of H3K27Me3 Demethylases in Immune Cell Differentiation
Bosselut, R. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.12.004 · Cited by 57
Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma
Hashizume, R. (2017) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2017-0018 · Cited by 63
EED orchestration of heart maturation through interaction with HDACs is H3K27me3-independent
Ai, S., Peng, Y., Li, C., Gu, F., Yu, X., Yue, Y., Ma, Q., Chen, J., Lin, Z., Zhou, P., et al. (2017) · eLife · doi:10.7554/elife.24570 · Cited by 53
Pilotto, S., Speranzini, V., Marabelli, C., Rusconi, F., Toffolo, E., Grillo, B., Battaglioli, E., & Mattevi, A. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw120 · Cited by 51
Jullien, J., Vodnala, M., Pasque, V., Oikawa, M., Miyamoto, K., Allen, G. E., David, S.-A., Brochard, V., Wang, S., Bradshaw, C. R., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.01.030 · Cited by 56
Boileau, M., Shirinian, M., Gayden, T., Harutyunyan, A. S., Chen, C. C. L., Mikael, L. G., Duncan, H. M., Neumann, A. L., Arreba-Tutusaus, P., Jay, N. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10705-z · Cited by 55
Glioma Stem Cells in Pediatric High-Grade Gliomas: From Current Knowledge to Future Perspectives
Da-Veiga, M.-A., Rogister, B., Lombard, A., Neirinckx, V., & Piette, C. (2022) · Cancers · doi:10.3390/cancers14092296 · Cited by 44
Not just a writer: PRC2 as a chromatin reader
Uckelmann, M., & Davidovich, C. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200728 · Cited by 44
Leatham-Jensen, M., Uyehara, C. M., Strahl, B. D., Matera, A. G., Duronio, R. J., & McKay, D. J. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1007932 · Cited by 42
A histone H3K9M mutation traps histone methyltransferase Clr4 to prevent heterochromatin spreading
Shan, C., Wang, J., Xu, K., Chen, H., Yue, J., Andrews, S. J., Moresco, J. J., Yates, J. R., Nagy, P. L., Tong, L., et al. (2016) · eLife · doi:10.7554/elife.17903 · Cited by 49
Diffuse midline glioma: review of epigenetics
Cooney, T. M., Lubanszky, E., Prasad, R., Hawkins, C. E., & Mueller, S. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03553-1 · Cited by 49
Maury, E., & Hashizume, R. (2017) · Epigenetics · doi:10.1080/15592294.2016.1278095 · Cited by 52
PRC2 engages a bivalent H3K27M-H3K27me3 dinucleosome inhibitor
Diehl, K. L., Ge, E. J., Weinberg, D. N., Jani, K. S., Allis, C. D., & Muir, T. W. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911775116 · Cited by 42
H3K36 methylation maintains cell identity by regulating opposing lineage programmes
Hoetker, M. S., Yagi, M., Stefano, B. D., Langerman, J., Cristea, S., Wong, L. P., Huebner, A. J., Charlton, J., Deng, W., Haggerty, C., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01191-z · Cited by 47
Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time
Filbin, M. G., & Suvà, M. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044208 · Cited by 51
H3K27M mutant glioma: Disease definition and biological underpinnings
Saratsis, A. M., Knowles, T., Petrović, A., & Nazarian, J. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad164 · Cited by 60
Navigating the complexity of Polycomb repression: Enzymatic cores and regulatory modules
Tamburri, S., Rustichelli, S., Amato, S., & Pasini, D. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.07.030 · Cited by 48
Oncohistones: Hijacking the Histone Code
Sahu, V., & Lü, C. (2022) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-102521 · Cited by 43
Invited Review: Emerging functions of histone H3 mutations in paediatric diffuse high‐grade gliomas
Kasper, L. H., & Baker, S. J. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12591 · Cited by 40
Separate Polycomb Response Elements control chromatin state and activation of the vestigial gene
Ahmad, K., & Spens, A. E. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1007877 · Cited by 41
Histone Lysine-to-Methionine Mutations Reduce Histone Methylation and Cause Developmental Pleiotropy
Sanders, D., Qian, S., Fieweger, R. A., Lü, L., Dowell, J. A., Denu, J. M., & Zhong, X. (2017) · PLANT PHYSIOLOGY · doi:10.1104/pp.16.01499 · Cited by 40
An, S., Camarillo, J. M., Huang, T. Y.-T., Li, D. D., Morris, J. A., Zoltek, M., Qi, J., Behbahani, M., Kambhampati, M., Kelleher, N. L., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01773-x · Cited by 34
Pereira, K. N. E., Shan, J., Licht, J. D., & Bennett, R. L. (2023) · Biochemical Society Transactions · doi:10.1042/bst20210567 · Cited by 41
Histone lysine demethylases in Drosophila melanogaster
Holowatyj, A., Yang, Z.-Q., & Pile, L. A. (2015) · Fly · doi:10.1080/19336934.2015.1074787 · Cited by 27
Histone H3.3 and cancer: A potential reader connection
Lan, F., & Shi, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418996111 · Cited by 34
Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma
Zhang, Q., Yang, L., Liu, Y. H., Wilkinson, J. E., & Krainer, A. R. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add8280 · Cited by 37
The Inherent Asymmetry of DNA Replication
Snedeker, J. C., Wooten, M., & Chen, X. (2017) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100616-060447 · Cited by 34
Polycomb repressive complex 2 in the driver’s seat of childhood and young adult brain tumours
Krug, B., Harutyunyan, A. S., Deshmukh, S., & Jabado, N. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.05.006 · Cited by 30
Funato, K., & Tabar, V. S. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050143 · Cited by 30
An epigenetic therapy for diffuse intrinsic pontine gliomas
Ramaswamy, V., Remke, M., & Taylor, M. D. (2014) · Nature Medicine · doi:10.1038/nm.3769 · Cited by 41
Mechanism of cancer: Oncohistones in action
Qiu, L., Hu, X., Jing, Q., Zeng, X., Chan, K. M., & Han, J. (2018) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2018.04.004 · Cited by 29
Sen, A., Gurdziel, K., Liu, J., Qu, W., Nuga, O. O., Burl, R. B., Hüttemann, M., Piqué-Regi, R., & Ruden, D. M. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00175 · Cited by 27
Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma
Katagi, H., Takata, N., Aoi, Y., Zhang, Y., Rendleman, E. J., Blyth, G. T., Eckerdt, F., Tomita, Y., Sasaki, T., Saratsis, A. M., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab009 · Cited by 34
Self-citationTargeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas
Vanan, M., Underhill, D. A., & Eisenstat, D. D. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0514-2 · Cited by 33
Mechanisms of Nucleosome Dynamics In Vivo
Henikoff, S. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026666 · Cited by 27
Lewis, N., Klein, R. H., Kelly, C., Yee, J. Q., & Knoepfler, P. S. (2022) · Epigenetics & Chromatin · doi:10.1186/s13072-022-00447-6 · Cited by 33
UBR7 acts as a histone chaperone for post‐nucleosomal histone H3
Hogan, A., Sathyan, K. M., Willis, A. B., Khurana, S., Srivastava, S., Zasadzińska, E., Lee, A. S., Bailey, A. O., Gaynes, M. N., Huang, J., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108307 · Cited by 21
Self-citationMendez, F., Núñez, F. J., Garcia-Fabiani, M. B., Haase, S., Carney, S. V., Gauss, J. C., Becher, O. J., Lowenstein, P. R., & Castro, M. G. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz218 · Cited by 27
Delaney, K., Strobino, M., Wenda, J. M., Pankowski, A., & Steiner, F. A. (2019) · Nature Communications · doi:10.1038/s41467-019-10404-9 · Cited by 23
Zhu, J., Ordway, A. J., Weber, L., Buddika, K., & Kumar, J. P. (2018) · Development · doi:10.1242/dev.160754 · Cited by 26
Symmetry from Asymmetry or Asymmetry from Symmetry?
Kahney, E. W., Ranjan, R., Gleason, R. J., & Chen, X. (2017) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2017.82.034272 · Cited by 26
Metadata
- Authors
- Herz, H.-M., Morgan, M., Gao, X., Jackson, J., Rickels, R., Swanson, S. K., Florens, L., Washburn, M. P., Eissenberg, J. C., & Shilatifard, A.
- Affiliations
- Stowers Institute for Medical Research (US)
- Saint Louis University (US)
- Corresponding author
- Herz, Hans-Martin
- Morgan, Marc
- Shilatifard, Ali
- Venue
- Science
- Published
- 2014-08-29
- Volume
- 345
- Issue
- 6200
- Pages
- 1065-1070
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4508193
- OpenAlex
- W2058818049
- Semantic Scholar
- cc46ffc8cf13a6bb6a94dcd9d3e80522bf04f88d
- Cited by
- 199
- References
- 37
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 12 · 2023: 12 · 2022: 14 · 2021: 20 · 2020: 20 · 2019: 23 · 2018: 17 · 2017: 27 · 2016: 17 · 2015: 11 · 2014: 4
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- H3K27M mutation, pediatric glioma, polycomb repressive complex 2, position effect variegation, heterochromatin silencing, H3K9 demethylation, histone methylation, Drosophila model
- MeSH terms
- Animals, Chromatin, Disease Models, Animal, Drosophila melanogaster, Glioma, Heterochromatin, Histones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.